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Compartmentalized Metabolic Engineering for Artemisinin Biosynthesis and
Effective Malaria Treatment by Oral Delivery of Plant Cells
Abstract
Artemisinin is highly effective against drug-resistant malarial parasites, which affects nearly half of the
global population and kills >500 000 people each year. The primary cost of artemisinin is the very
expensive process used to extract and purify the drug from Artemisia annua. Elimination of this
apparently unnecessary step will make this potent antimalarial drug affordable to the global population
living in endemic regions. Here we reported the oral delivery of a non-protein drug artemisinin
biosynthesized (~0.8 mg/g dry weight) at clinically meaningful levels in tobacco by engineering two
metabolic pathways targeted to three different cellular compartments (chloroplast, nucleus, and
mitochondria). The doubly transgenic lines showed a three-fold enhancement of isopentenyl
pyrophosphate, and targeting AACPR, DBR2, and CYP71AV1 to chloroplasts resulted in higher expression
and an efficient photo-oxidation of dihydroartemisinic acid to artemisinin. Partially purified extracts from
the leaves of transgenic tobacco plants inhibited in vitro growth progression of Plasmodium
falciparum-infected red blood cells. Oral feeding of whole intact plant cells bioencapsulating the
artemisinin reduced the parasitemia levels in challenged mice in comparison with commercial drug. Such
novel synergistic approaches should facilitate low-cost production and delivery of artemisinin and other
drugs through metabolic engineering of edible plants.

Keywords
bioencapsulation, oral delivery of plant material, dihydroartemisinic acid, isopentenyl pyrophosphate,
plant transformation, drug biosynthesis

Disciplines
Dentistry

Author(s)
Karan Malhotra, Mayavan Subramaniyan, Khushboo Rawat, Md. Kalamuddin, M. Irfan Qureshi, Pawan
Malhotra, Asif Mohmmed, Katrina Cornish, Henry Daniell, and Shashi Kumar

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/dental_papers/286

HHS Public Access
Author manuscript
Author Manuscript

Mol Plant. Author manuscript; available in PMC 2018 May 31.
Published in final edited form as:
Mol Plant. 2016 November 07; 9(11): 1464–1477. doi:10.1016/j.molp.2016.09.013.

Compartmentalized Metabolic Engineering for Artemisinin
Biosynthesis and Effective Malaria Treatment by Oral Delivery of
Plant Cells

Author Manuscript

Karan Malhotra1, Mayavan Subramaniyan1, Khushboo Rawat2, Md. Kalamuddin2, M. Irfan
Qureshi3, Pawan Malhotra2, Asif Mohmmed2, Katrina Cornish4, Henry Daniell5, and Shashi
Kumar1,*
1Metabolic

Engineering Group

2Malaria

Research Group International Centre for Genetic Engineering and Biotechnology, Aruna
Asaf Ali Marg, New Delhi 110067, India

3Department

of Biotechnology, Jamia Millia Islamia, New Delhi 110025, India

4Department

of Horticulture and Crop Science, The Ohio State University, Wooster, OH 44691,

USA
5Department

of Biochemistry, School of Dental Medicine, University of Pennsylvania,
Philadelphia, PA 19104, USA

Author Manuscript

Abstract

Author Manuscript

Artemisinin is highly effective against drug-resistant malarial parasites, which affects nearly half
of the global population and kills >500 000 people each year. The primary cost of artemisinin is
the very expensive process used to extract and purify the drug from Artemisia annua. Elimination
of this apparently unnecessary step will make this potent antimalarial drug affordable to the global
population living in endemic regions. Here we reported the oral delivery of a non-protein drug
artemisinin biosynthesized (~0.8 mg/g dry weight) at clinically meaningful levels in tobacco by
engineering two metabolic pathways targeted to three different cellular compartments (chloroplast,
nucleus, and mitochondria). The doubly transgenic lines showed a three-fold enhancement of
isopentenyl pyrophosphate, and targeting AACPR, DBR2, and CYP71AV1 to chloroplasts resulted
in higher expression and an efficient photo-oxidation of dihydroartemisinic acid to artemisinin.
Partially purified extracts from the leaves of transgenic tobacco plants inhibited in vitro growth
progression of Plasmodium falciparum-infected red blood cells. Oral feeding of whole intact plant
cells bioencapsulating the artemisinin reduced the parasitemia levels in challenged mice in
comparison with commercial drug. Such novel synergistic approaches should facilitate low-cost
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production and delivery of artemisinin and other drugs through metabolic engineering of edible
plants.

Keywords
bioencapsulation; oral delivery of plant material; dihydroartemisinic acid; isopentenyl
pyrophosphate; plant transformation; drug biosynthesis
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Artemisinin-based combination therapies, commonly referred to as ACTs, are the frontline
treatments in the fight against malaria (Dalrymple, 2013). Besides the antiplasmodial
activity of artemisinin and its semi-synthetic derivative artesunate, the drug has
demonstrated cytotoxicity against cancer cells and schistosomiasis (Efferth, 2006; Utzinger
et al., 2007; Efferth et al., 2011). A notable broad-spectrum activity of artesunate has been
reported against human cytomegalovirus, which has become resistant to traditional drugs
such as ganciclovir (Shapira et al., 2008). However, these therapies are not readily available
to patients in endemic regions due to the low yield of artemisinin from the native plant.
Artemisinin is biosynthesized mainly in the glandular trichomes on leaves. Three key
enzymes of artemisinin biosynthesis were exclusively expressed in apical cells of glandular
trichomes but not in the subapical chloroplast-containing cells, although all of these cells did
express the farnesyl pyrophosphate synthase (Olsson et al., 2009). Artemisinin production in
aerial parts of the plant is sensitive to variation in genetic backgrounds, cultivation
conditions, and harvesting periods. Its biosynthesis is stimulated by biotic and abiotic stress
(Ferreira et al., 1995; Davies et al., 2009, 2011). The yield of artemisinin (~0.5% on dry
weight basis) from Artemisia annua is relatively low when cultivated under Indian climatic
conditions (Brisibe and Chukwurah, 2014), which limits its commercial production and
value. Even the high-yield variety “CIM-Arogya,” developed for marker-assisted breeding,
has maximum reported yields of ~1% in Indian conditions (Khanuja et al., 2008). Endeavors
to increase artemisinin levels in A. annua by elicitor or hormone treatments (Smith et al.,
1997; Baldi and Dixit, 2008) have met with limited success, and present efforts rely mostly
on marker-assisted breeding of high-yield varieties (Graham et al., 2010). Low yields of
artemisinin from crop-based production systems and the high cost of chemical synthesis,
make these approaches impractical for commercial production (Enserink, 2005; White,
2008). Further to these issues, yearly variations in the availability of starting raw materials
and unpredictable demand for this antimalarial agent greatly affect the price of artemisinin
(Kindermans et al., 2007). Thus, alternative heterologous production platforms should be
explored to address these issues. Attempts have been made to produce its precursor,
amorphadiene, via metabolic engineering of Escherichia coli with the mevalonate (MEV)
pathway and the amorphadiene synthase gene (ADS). Unfortunately, transgene expression
inhibited E. coli growth, resulting in very low amorphadiene levels (Martin et al., 2003). The
semi-synthetic approach in yeast yielded a high level of artemisinic acid, a precursor of
artemisinin (Paddon et al., 2013), but complete biosynthesis of artemisinin was not
accomplished. Expression of artemisinin is difficult in microbial hosts, mainly due to lack of
plant cytochrome P450. The successive oxidation of amorphadiene to artemisinic alcohol is
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catalyzed by a cytochrome P450 oxidase gene (CYP71AV1). Artemisinin biosynthesis is
favored through the dihydroartemisinic acid (DHAA) biosynthetic pathway using double
bond reductase 2 (DBR2), which reduces the Δ11(13) double bond of artemisinic aldehyde
(Covello, 2008; Zhang et al., 2008). The conversion of DHAA to artemisinin is a nonenzymatic photochemical oxidation process (Brown and Sy, 2004).

Author Manuscript

Tobacco became our platform of choice because artemisinin is a plant product and other
terpenoids have successfully been expressed (Ikram et al., 2015). Tobacco is a large plant
that can be harvested several times a year and can be grown as a perennial. Each plant
produces nearly a million seeds per season, so production acreage can be rapidly scaled up
for the low costs production of pharmaceuticals (Arlen et al., 2007). The constitutive
expression of the ADS gene in Nicotiana tabacum has been achieved (Wallaart et al., 2001)
but very low levels of amorphadiene biosynthesis were realized (<2 ng/g of fresh weight).
Recently, the complete biosynthesis of artemisinin was reported in N. tabacum via nuclear
transformation by expressing CYP71AV1 and cytochrome P450 reductase (CPR), along with
ADS, DBR2, and a deregulated form of HMGR (Farhi et al., 2011a). However, artemisinin
levels were found to be low in these transgenic lines (6.8 μg/g dry weight), which may be
attributed to a limiting pool of isopentenyl pyrophosphate (IPP).
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Subcellular targeting of ADS to mitochondria significantly improved the accumulation of
amorphadiene (Wu et al., 2006; van Herpen et al., 2010; Farhi et al., 2011b). These studies
showed that farnesyl pyrophosphate (FPP) (a precursor to amorphadiene) is readily available
in different cellular compartments and could be utilized for amorphadiene and artemisinin
biosynthesis. Chloroplasts offer an ideal platform for accumulating large amounts of IPP and
overcome substrate limitations apparent in the cytosol. Homoplastomic plants engineered
with the MEV pathway accumulate higher levels of mevalonate than untransformed plants
(Kumar et al., 2012). Previously, we attempted to achieve complete artemisinic acid
biosynthesis in tobacco chloroplasts by introducing both MEV and artemisinic acid
pathways (~12 genes). Unfortunately, this approach resulted in a low yield of artemisinic
acid and stunted the growth of transgenic plants (Saxena et al., 2014), possibly because of
suppression of one of the added pathways or precursor limitations.
To overcome these limitations, we developed a novel strategy for complete artemisinin
biosynthesis in tobacco through combining expression in both chloroplast and nuclear
genomes (Figure 1). The stable doubly transgenic (DT) plants produced adequate levels of
artemisinin, and drug functionality was studied on the malarial parasite Plasmodium using in
vitro and in vivo assays.

Author Manuscript

RESULTS
Confirmation of Plant Transformation and Molecular Analysis
Homoplastomic plants expressing the mevalonate pathway grew similarly to wild-type
plants in the greenhouse, without observable phenotypic abnormality (Supplemental Figure
1C). The functionality of the yeast mevalonate biosynthetic pathway in T-MEV plants was
confirmed by treatment of transplastomic plants with selection medium containing 100 μM
fosmidomycin, a specific inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase
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(DXR). These transplastomic plants thrived (Supplemental Figure 1D, right), while the wildtype plants had stunted growth and bleached leaves (Supplemental Figure 1D, left),
confirming that IPP was produced in chloroplast by the genetically engineered mevalonate
pathway (Supplemental Figure 1D, right).

Author Manuscript

Twelve independent nuclear transgenic lines were regenerated on double-selection media
when T-MEV was re-transformed via Agrobacterium tumefaciens (strain EHA105)
harboring a binary vector pNuc-Cox-Art containing DHAA biosynthetic pathway genes
(Figure 2A). PCR analysis using ADS and DBR2 gene-specific primers confirmed the
integration of transgenes into the nuclear genome in all 12 DT plants. All transgenic lines
showed 539-bp and 441-bp amplicons for ADS and DBR2, respectively (Figure 2B). No
PCR amplification product was observed in wild-type plants. All DT plants grew normally
and set flowers and fertile seeds (Figure 2C). No morphological abnormality was observed
in DT plants with respect to growth pattern, leaf size, or plant height when compared with
wild-type plants. However, there was a decrease in the total chlorophyll and carotenoid
content in all DT lines (DT1–DT4), with DT2 and DT4 showing the lowest pigment levels
(Supplemental Figure 6A). Pigment levels were unaffected in the T-MEV plants. Maximum
quantum yield (Fv/Fm), i.e., photosynthetic performance, was marginally lower in all DT
lines (except DT3 and T-MEV) (Supplemental Figure 6B). The effective quantum yield, or
Y(II) and Y(NPQ), or quantum yield of regulated energy dissipation, was lower for DT3 and
T-MEV plants (Supplemental Figure 6C) than for the other DT plants or the wild type. As
predicted, only T1 seeds from DT plants were able to grow on double-selection RMOP
medium containing hygromycin (50 mg/l) and spectinomycin (500 mg/l) (Figure 2D).
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The highest yield of artemisinin was observed in four lines, named DT1 to DT4, ranging
from 0.3 to 0.8 mg/g dry weight. All four lines (DT1–DT4) contained a single integrated
copy of the DHAA biosynthetic transgene cassette (Figure 2E). Amplicon signals of 219 bp
for ADS, 281 bp for DBR2, 190 bp for CYP71AV1, and 275 bp for AACPR were observed
in greenhouse-grown DT1–DT4 plants (Figure 2F), confirming nuclear expression.
Production of Artemisinin, DHAA, IPP/Dimethylallyl Pyrophosphate, and Amorphadiene in
Transformed Plants

Author Manuscript

All doubly transgenic (DT) lines accumulated artemisinin except DT9 and DT10
(Supplemental Table 3). Maximum biosynthesis was observed in DT1, DT2, DT3, and DT4.
These lines accumulated artemisinin due to the non-enzymatic reaction of photo-oxidation
of DHAA (Figure 3B), while no such accumulation was observed in wild-type tobacco
plants (Figure 3A). The levels of artemisinin in the four transgenic lines varied between 0.3
and 0.8 mg/g dry weight (n = 3). The artemisinin content was highest in DT4 (Figure 3B and
3C) plants, about 0.8 mg/g dry weight (n = 3). The product ion (MS2) spectra of artemisinin
in DT4 plant is mentioned in Supplemental Figure 2B. Such variation in transgene
expression among nuclear transgenic lines is expected and occurs due to positional effects,
gene silencing, and other regulatory controls.
We analyzed the synthesis of two intermediates of the artemisinin biosynthetic pathway,
namely DHAA and IPP, in the transgenic lines DT1–DT4. A peak corresponding to the
retention time of DHAA was observed in both a DHAA standard (Figure 4A) and an extract
Mol Plant. Author manuscript; available in PMC 2018 May 31.
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of A. annua (Figure 4C). Interestingly, an additional peak at 5.2 min was observed in the
DTs (Figure 4B), which matched the chromatographic profile of A. annua (Figure 4C) used
as a control. However, this additional peak was not observed in the authentic standard of
DHAA (Figure 4A). Maximum DHAA accumulation observed was in DT4, up to 150 μg/g
dry weight (Figure 4B).
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Intermediate metabolite IPP synthesis in the DTs was compared with the wild-type plants,
using an authentic standard of IPP (Supplemental Figure 3B) by liquid chromatography–
tandem mass spectrometry (LC–MS/MS). The DT plants accumulated more IPP (Figure
5C–5E) than the wild type (Figure 5A) and T-MEV plants (Figure 5B). The mean amount of
IPP ranged from 0.1 to 2.5 μg/g fresh weight in DTs, compared with only ~0.07 μg/g fresh
weight in the wild type (n = 3, Figure 5G). The intermediate volatile metabolite
amorphadiene was detected in DTs by gas chromatography (GC)–MS by comparing the
mass spectra with the standard (Figure 6A and 6B). The transgenic line DT4 (Figure 6A,
upper chromatogram) had the highest amorphadiene levels, up to 60 μg/g dry weight.
However, absolute quantification of this compound is difficult due to the volatile nature of
amorphadiene (Beale et al., 2006; van Herpen et al., 2010).
In Vitro Anti-parasitic Activity of Artemisinin Produced by DTs
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Partially purified transgenic plant extracts of DT lines inhibited the growth of parasites after
24 and 48 h (Figure 7A). Few or no new ring-stage parasites, and dead parasites with
constricted and shrunken morphology, were observed (Figure 7A). In comparison, parasite
cultures treated with either DMSO or with an extract from wild-type plants grew normally.
The merozoites released from schizonts further invaded fresh red blood cells (RBCs) and
formed new rings by 48 h (Figure 7A). Extract from DT4, which contained the highest
artemisinin level, was most effective, with IC50 ~79 nM (Figure 7B; see also Supplemental
Figure 4).
Efficacy of Artemisinin-Producing Plant Extracts in the P. berghei Mouse Model

Author Manuscript

The in vivo anti-malarial efficacy of DT plant extracts was analyzed using the Plasmodium
berghei murine malaria model. Infected mice were fed with dried intact plant cells using a
gavage needle, and parasitemia was evaluated every day until day 15. Parasitemia profiles of
mice treated with transgenic plants were compared with mice fed with pure artemisinin drug
or wild-type plant extracts. Similar progression in parasitemia was observed in mice fed with
pure artemisinin as well as those fed with the wild-type plant extract (Figure 7C), the control
group. However, mice fed with crushed DT leaves showed a considerable delay in
progression of parasitemia, most notable in mice fed with DT4 on the 10th day post
infection. A significant reduction in parasitemia from ~2.5% to ~1.6% was observed when
compared with mice fed pure artemisinin (Figure 7C). In addition, mice fed with DT4 leaf
material did not show any sign of malarial sickness during the first week of infection, while
mice fed with pure artemisinin or wild-type plants had malarial symptoms. Together, these
results show that DT leaf material considerably delayed the development of parasitemia in
mice and that this delay was longer than that induced by pure artemisinin.
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In our previous study (Saxena et al., 2014), expression of all the 12 transgenes into the
tobacco chloroplast genome caused stunted growth, which highlighted the need to spread the
biosynthetic load to more than one metabolic compartment. We circumvented these defects
by using a balanced compartmentalization approach to transgene expression using three
cellular compartments (cytosol, chloroplast, and mitochondria), and obtained DT plants with
normal phenotypes and up to 0.8 mg artemisinin per gram dry weight leaf. A similar effort
using combinatorial super transformation of transplastomic lines engineered with the
artemisinic acid pathway resulted in an accumulation of 120 μg/g fresh weight of artemisinic
acid (Fuentes et al., 2016). Low artemisinin accumulation in tobacco in earlier reports was
thought to be either due to a high level of glycosylation by endogenous glycosyl transferases
(van Herpen et al., 2010; Ting et al., 2013) or unfavorable cytosolic environmental
conditions preventing the formation of late-stage artemisinin precursors (Zhang et al., 2011).
The transgenes AACPR, CYP71AV1, and DBR2, beyond ADS, were targeted to the
chloroplast in our study because it is a glycosylation-free compartment. Thus, chloroplasts
offer ideal sites for accumulation of complex transgene products that may otherwise be
harmful if accumulated in the cytosol (Bogorad, 2000). The use of intense light during
greenhouse cultivation and harvesting of DT lines may have favored the bioconversion of
DHAA to artemisinin by photo-oxidation (Farhi et al., 2011b). Also, the excess pool of IPP/
dimethylallyl pyrophosphate (DMAPP), produced in the DT plants (via T-MEV pathway
and IDI gene expressed in chloroplast and nuclear genome, respectively) may have helped
produce the higher end product. We hypothesize that compartmentalization, subcellular
targeting of artemisinin biosynthetic enzymes to chloroplasts, and a surplus amount of
endogenous IPP (Figure 5B) are key to producing much higher levels of artemisinin than
previously reported (Supplemental Table 2).
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All terpenoids, including artemisinin, are synthesized from two isoprenoid precursors, IPP
and DMAPP. However, the synthesis of IPP by the MEV pathway is tightly regulated due to
its need to supply diverse metabolic processes (Goldstein and Brown, 1990). The limited,
wild-type, IPP pool is unlikely to permit DHAA accumulation and would result in the little
biosynthesis of artemisinin. LC–MS/MS measures the total amount of IPP and DMAPP as
both the metabolites are allylic isomers with the same parent mass, i.e., 245 Da (Li and
Sharkey, 2013); thus, in our analysis the total amount of IPP and DMAPP was quantified
(Figure 5A–5G). The IDI gene (IPP/DMAPP isomerase) was introduced into the nuclear
genome, which may have helped to maintain a favorable equilibrium between IPP and
DMAPP, and normal physiological functions in eukaryotes (Koyama et al., 1983; Lützow
and Beyer, 1988). Moreover, reduced IDI activity affects isoprenoid biosynthesis in the
plastids of tobacco leaves and results in depletion of photosynthetic pigments (Page et al.,
2004). Amorphadiene is the first committed precursor in the artemisinin biosynthetic
pathway. Previous reports suggest that fusion of sesquiterpene synthases with cox4 results in
elevated levels of sesquiterpenoid production because of the considerable pool of FPP found
in mitochondria (Kappers et al., 2005; Farhi et al., 2011b). Therefore, to enhance
amorphadiene synthesis, the ADS gene was fused with mitochondrial signal peptide (cox4),
and this did result in higher amorphadiene biosynthesis (Figure 6A).
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Previously, we have reported the expression of individual transgenes related to the MEV
pathway in chloroplasts (Kumar et al., 2012). The RT–PCR study was conducted for mRNA
analysis for determining the expression of other essential transgenes (DBR2, ADS, AACPR,
and CYP71AV1). The weak correlations between mRNA and protein expression are
attributed to various post-transcriptional processes that complicate accurate estimates of
quantities of the corresponding mRNAs destined for translation (Gry et al., 2009; Vogel and
Marcotte, 2012). Furthermore, it may be difficult to decipher accumulation of individual
metabolites in chloroplasts using the metabolomics approach, as native MEV/MEP
(methylerythritol-4-phosphate) pathways also function in plants.
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Studies on A. annua high-artemisinin-producing and low-artemisinin-producing chemotypes
suggest different biosynthetic routes beyond artemisinic aldehyde intermediate (Bertea et al.,
2005; Covello, 2008). The two chemotypes had different CYP71AV1 enzyme activities
(Ting et al., 2013), and the activity of the Dbr2 promoter also was implicated (Yang et al.,
2015). We chose a strong constitutive promoter, the 35S promoter of CaMV with double
enhancer, to drive the expression of Dbr2 gene and thereby generate excess DBR2
transcripts, to favor artemisinic aldehyde flux toward DHAA and eventually artemisinin
biosynthesis.
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There were no adverse effects on the growth or morphology of DT plants producing
artemisinin (Supplemental Figure 6A), and the minor decrease in pigments had no
observable effect on the whole plants. Nonetheless, the pigment decrease in DT2 and DT4
may have been caused by the consumption of IPP by the artemisinin pathway. The
marginally lower Y(NPQ), in DT3, most likely explains the reduced Y(II) value
(Supplemental Figure 6C). In general, a high Y(NPQ) value indicates that plants are more
adapted to light stress and more efficiently direct it toward photosynthesis (Gao et al., 2011).
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In our case, the co-expression of two pathways did not imbalance plant metabolism to a
sufficient degree to cause gross aberrant effects. This is in contrast to a recent report, which
found extensive off-target effects induced by overexpression, in tobacco, of FPP synthase
and squalene synthase in the cytosol, chloroplast, or both. Their large changes were
attributed to metabolite-mediated anterograde and/or retrograde signaling regardless of the
level of transgene expression or end product, due to imbalanced metabolic pools (Pasoreck
et al., 2016). These negative impacts were not related to the number of genes expressed or
the level of expression. However, it is possible that our co-expression strategy to increase the
pool IPP and the physiological regulator IDI provided the observed metabolic balance not
observed by Pasoreck et al. (2016). IPP does appear to pass between the chloroplastic and
cytosolic compartments independent of the synthetic site (Bick and Lange, 2003; Dudareva
et al., 2005; Kumar et al., 2012). This is supported by our study on the levels of squalene in
untransformed (wild-type), chloroplast transformed (T-MEV), and chloroplast and nuclear
transformed (DT) plants. GC–MS/MS analysis showed a significant increase in the overall
yield of squalene in DT and T-MEV plants compared with wild-type plants (Supplemental
Figure 7), which could be due to a unidirectional transport of metabolites across the
chloroplast envelope membrane or to direct effects of excess FPP. However, low levels of
squalene were present in the high-artemisinin-producing DT2 and DT4 (Table 1), indicating
a preferential consumption of IPP and FPP by the artemisinin pathway in these plants.
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The primary cost of artemisinin is the very expensive process used to extract and purify the
drug from A. annua. Our report indicates that this is an unnecessary step and that artemisinin
can be produced in edible leaves. We provide a proof-of-concept demonstration of the
functionality of tobacco-biosynthesized artemisinin in DT lines. This finding suggests that
artemisinin can become accessible and affordable to the large global population living in
malarial regions. Malaria remains a global health problem with nearly 3.2 billion people at
risk (almost half of the world’s population) (http://www.who.int/mediacentre/factsheets/
fs094/en/). Results demonstrated through in vitro (Figure 7A) and in vivo animal studies
(Figure 7A and 7B) are critical for functional evaluation of foreign products expressed in
plants.
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Earlier reports had shown that none of the substances in tobacco leaves, including nicotine,
reduced the parasitemia load when wild-type tobacco leaves were fed orally to mice
(Davoodi-Semiromi et al., 2010). Mice fed orally with extracts from wild-type and
commercially available pure drug resulted in similar parasite loads. This was probably due
to the poor bioavailability of the pure (commercial) artemisinin, which is rapidly degraded
by hepatic and intestinal cytochrome enzymes (Svensson and Ashton, 1999). The enhanced
efficacy of artemisinin delivered via intact whole-plant DT4 leaves compared with pure
(commercial) artemisinin is probably due to the bioencapsulation of this bioactive
compound. A previous report on the oral feeding of A. annua (Weathers et al., 2014; Elfawal
et al., 2015) suggested that higher efficacy of orally fed A. annua leaves could be due to the
protection of flavonoids or other antioxidants present in plants or animal feed. We have
previously shown that plant cells protect biopharmaceuticals from acids and enzymes in the
stomach via bioencapsulation. The gut microbes release these drugs in the gut lumen by the
action of commensal microbes, where they are absorbed and delivered to the blood
circulation system (Limaye et al., 2006; Kwon et al., 2013; Kohli et al., 2014; Sherman et
al., 2014; Shil et al., 2014). Human digestive enzymes are incapable of breaking down
glycosidic bonds in plant cell wall carbohydrates, and this process is performed by the gut
microflora, which has evolved to break down every component of plant cell wall (Flint et al.,
2008; Martens et al., 2011). Similarly, when intact plant tissue and cells containing drugs
reach the gut, commensal microbes gradually digest plant cell walls and release drugs
relatively slowly. Furthermore, DT plants biosynthesized both DHAA and artemisinin.
DHAA has been shown to have higher bioavailability when compared with pure artemisinin
and may play a critical role in the treatment of malaria (Li et al., 1998). However, for clinical
translation, this concept should be transferred to proven edible plants for oral delivery
studies (Kwon and Daniell, 2016).
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Several other biopharmaceuticals have been made in tobacco leaves for the treatment of
infectious diseases such as tuberculosis (Lakshmi et al., 2013), cholera (Davoodi-Semiromi
et al., 2010), anthrax (Watson et al., 2004; Koya et al., 2005), and plague (Arlen et al.,
2008). These could only be tested under field conditions under USDA-APHIS approval
(Arlen et al., 2007). Chloroplast engineering is not regulated by USDA-APHIS because this
approach does not use plant pathogens or pathogen regulatory sequences (Chan and Daniell,
2015; Kwon and Daniell, 2015). Therefore, DT lines, as created in our study, may have
significant regulatory advantages for further development.
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In conclusion, we have achieved biosynthesis of the potent anti-malarial drug, artemisinin, in
tobacco plants at enhanced levels (~0.8 mg/g dry weight) by introducing two megabiosynthetic pathways separately into the chloroplast and nuclear genomes, without
perturbing the plant health. This is the first report of sequential chloroplast and nuclear
genome transformation successfully expressing two mega-biosynthetic pathways and
accomplishing complete artemisinin biosynthesis in an alternative host plant.
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Most importantly, we report the stability of biosynthesized artemisinin bioencapsulated in
plant cells upon oral delivery. The functionality of tobacco DT leaf artemisinin (fed as
crushed leaves) was demonstrated by in vitro and in vivo antimalarial efficacy studies and
was considerably better than pure artemisinin. This could significantly increase drug
effectiveness and lower the cost of malaria treatment. Malaria disproportionately affects low
socio-economic areas and children, the most susceptible to this disease, die in their millions
every year. A similar approach could be extended to edible crops, such as lettuce, for
artemisinin biosynthesis, and delivering the drug orally may provide a low-cost,
environmentally friendly, and supplementary source of bioencapsulated artemisinin,
eliminating expensive extraction and purification processes.

METHODS
Construction of Plant Transformation Vectors
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The tobacco-specific chloroplast transformation vector (pCT-MEV) was designed as
reported by Kumar et al. (2012). The nuclear transformation vector pCox-Nuc-Art was
designed in silico, and contains the genes IDI (IPP/DMAPP isomerase; gi|4633512), FPP
synthase (gi|216582) from E. coli, a modified amorpha-4,11-diene synthase gene (Anthony
et al., 2009), amorpha-4,11-diene C-12 oxidase (CYP71AV1, gi|82548247), the A. annua
cytochrome P450 reductase (AACPR, gi|83854016), and the double bond reductase-2
(DBR2; gi|494114616). Supplemental Figure 5 contains the entire sequence of vector pCoxNuc-Art. For efficient expression, each gene was placed under the control of an individual
promoter. The APX constitutive promoter (Park et al., 2010) drives the expression of IDI.
CYP71AV1 and DBR2 were controlled by double enhancer CaMV 35S promoter (Guilley et
al., 1982) while FPP and AACPR were driven by the CsVMV promoter. The hpt II gene,
conferring resistance to hygromycin, was placed under the control of CaMV 35S promoter.
The DHAA transgene cassette was released from the pUC57 plasmid by double digestion
and ligated into the binary vector pCAMBIA1300 (kindly provided by Dr. Narendra Tuteja,
ICGEB, New Delhi). Positive clones, confirmed by restriction digestion using enzymes
BamHI and HindIII (NEB, USA), were electroporated into Agrobacterium strain EHA105
for nuclear transformation of the T-MEV plants. Transformants were selected on Luria–
Bertani plates containing 50 mg/l kanamycin and 10 mg/l rifampicin. In addition, the ADS
gene was targeted to mitochondria by use of cox4 mitochondrial signal peptide. AACPR and
CYP71AV1 genes were targeted to chloroplasts using a chloroplast transit peptide (gi|20023|
emb|X02353.1| Tobacco gene for ribulose 1,5-bisphosphate carboxylase small subunit) and
the DBR2 gene was targeted to chloroplasts by the rbcS1 transit peptide.
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Transformation and Selection of Tissues
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Chloroplast transformation was performed in Nicotiana tabacum cv. Petit Havana SR1
leaves with pCT-MEV vector using S550d gold particles according to manufacturer’s
instructions (Seashell Technology, CA, USA). Transgenic tissues were selected on RMOP
medium containing spectinomycin (500 mg/l). Homoplasmy in the transformed plants (TMEV) was obtained on antibiotic-containing selection medium. For nuclear transformation,
homoplastomic tobacco plants (containing the yeast mevalonate pathway) were retransformed with Agrobacterium tumefaciens (strain EHA105) containing a pCox-Nuc-Art
vector. The doubly transformed tissues were selected on RMOP medium containing 50 mg/l
hygromycin and 500 mg/l spectinomycin.
Molecular Analysis of Double Transformants
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To test integration of the DHAA biosynthetic cassette, we tested doubly transformed tobacco
plants for transgene integration by PCR using gene-specific primers. Primers for ADS and
DBR2 are listed in Supplemental Table 1 and were synthesized according to their gene
sequence (Sigma, Bengaluru, India).
Southern Blot Analysis of Double Transformants
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Prior to nuclear transformation, homoplasmy of the engineered MEV pathway in the T-MEV
plants was confirmed by Southern blot. A hybridization fragment, corresponding to 5.5 kb in
the T-MEV plants, confirmed the homoplastomic status of transgenic plants (Supplemental
Figure 1B). The hybridization fragment, corresponding to 1.4 kb, represented the native
chloroplast genome of wild-type control plants (Supplemental Figure 1B). Transgene copy
number in greenhouse-grown, DT plants carrying the pCox-Nuc-Art vector was determined
using Southern blots following the DHAA and artemisinin biosynthesis study. Genomic
DNA (~15 μg), was isolated from transgenic plants DT1–DT4 and control wild-type plants
using a modified CTAB method (Porebski et al., 1997). It was digested overnight with
EcoRV and separated on a 0.8% agarose gel. It was further transferred to Hybond N+
membranes (GE Healthcare, Buckinghamshire, UK). A PCR-amplified DBR2 gene (441 bp)
was used as a probe (Figure 2A). Probe labeling of DNA blots was carried out using the
AlkPhos direct-labeling kit, and signals were detected with the CDP-Star detection reagent
(GE Healthcare).
RNA Transcript Analysis
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Total RNA was isolated from wild-type and DT1–DT4 plants using the RNeasy Plant Mini
Kit (Qiagen) according to the vendor’s instructions. Total RNA was treated with DNase
(Qiagen) to remove any remaining genomic DNA contamination. The cDNA synthesis from
RNA was carried using the SuperScript III First-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA, USA). The resulting cDNA was amplified using gene-specific primers
(Supplemental Table 1) to examine the mRNA transcripts of the transgenes introduced into
the nuclear genome of DT plants.
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Analysis of Artemisinin and Intermediate Metabolites
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Artemisinin and DHAA levels in leaves of greenhouse-grown DT plants were determined by
LC–MS/MS (Suberu et al., 2013), using an Agilent 1200 series reverse-phase C-18 column
(4.6 × 100 mm × 3.5 μm) at a flow rate of 0.8 ml/min coupled with a 3200 Q TRAP linear
ion trap mass spectrometer (Applied Biosystems, ABSCIEX, Singapore), equipped with a
TurboIon spray source. Data were acquired and evaluated by Analyst software (version 1.6,
ABSCIEX, Singapore). The MS was operated in positive mode and in MRM (Multiple
Reaction Monitoring) mode. Declustering potential (DP), collision energy (CE), and
collision cell exit potential (CXP) of each transition were optimized. The major MS/MS
fragmentation patterns of both artemisinin (Supplemental Figure 2A) and DHAA were
determined. For optimization of MS-dependent parameters, artemisinin (Sigma, Bengaluru,
India) and DHAA (Apin Chemicals, Oxon, UK) standards in acetonitrile were injected
separately using a gas-tight syringe (Harvard Apparatus, Holliston, USA). Quantification
was done using MultiQuant software (Colangelo et al., 2013) and the R2 value was 0.9987.
Analysis of IPP and DMAPP
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Wild-type and DT leaves were lyophilized. Approximately 1 g of each sample was crushed
in liquid nitrogen and extracted on ice, for 30 min in methanol (5 ml) in a water bath
sonicator (Branson Ultrasonic, Danbury, USA). An IPP (Sigma, Bengaluru, India) standard
was diluted with methanol to optimize MS-dependent parameters. The MS was operated in
negative ion and MRM mode. Pure IPP was infused at a flow rate of 10 μl/min by a gas-tight
syringe (Harvard Apparatus, Holliston, USA). The major MS/MS fragment for IPP
(Supplemental Figure 3A), DP, CE, and CXP for each transition were optimized. MRM
mode was used to quantify IPP in each sample using MultiQuant software (Colangelo et al.,
2013). Metabolites were separated using an Agilent 1200 series reverse-phase C-18 column
(4.6 × 100 mm × 3.5 μm) at a flow rate of 0.8 ml/min.
GC–MS Analysis of Amorphadiene

Author Manuscript

Leaves from the greenhouse-grown wild-type and DT plants (μ1 g) were crushed in liquid
nitrogen and extracted with ethyl acetate (2 ml) for 30 min in a water bath sonicator
(Branson Ultrasonic, Danbury, USA). The extracts were concentrated by evaporation under
nitrogen. A 1-μl aliquot from the extract was analyzed by GC–MS, using an Agilent 7890A
with an HP-5 column (30 m × 0.25 mm internal diameter, 0.25 μm film thickness) and a
7000C triple quadrupole GC–MS/MS spectrometer. The MS was operated in electron
ionization mode and scanning mode (50–500 m/z). Amorphadiene was detected by
comparing the retention time and mass spectra with an authentic standard (kindly provided
by Amyris Biotechnology, Emeryville, CA, USA).
In Vitro Functionality of Artemisinin against P. falciparum
Malarial parasite in vitro assays were conducted to test the functionality of DT tobaccoproduced artemisinin. A Plasmodium falciparum 3D7 culture was synchronized to the ring
stage by two consecutive sorbitol treatments separated by 4 h, then cultured for 40 h and
allowed to re-invade RBCs and cultured in RPMI-1640 medium (Gibco BRL, Grand Island,
USA). Growth inhibition of the P. falciparum 3D7 cultures was determined by the SYBR
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Green assay (Smilkstein et al., 2004). In brief, a parasite culture with an initial parasitemia
of 1%, in 2% hematocrit, was treated with different doses of DT tobacco artemisinin in 96
well plates, each well containing 100 μl of culture of parasite-infected RBCs. DMSO and
commercially sourced artemisinin (Sigma-Aldrich, Bengaluru, India) served as negative and
positive controls, respectively. Plates containing DT plant extracts and parasites were
incubated at 37°C for 48 h. Parasite growth progression was monitored by preparing
Giemsa-stained blood smears after 24 h and 48 h. After each time point, 100 μl of lysis
buffer (20 mM Tris, 5 mM EDTA, 0.008% saponin, 0.08% Triton X) containing 1×SYBR
Green, was added to the cultures and incubated at 37°C for 1 h. Fluorescence was read using
a PerkinElmer Victor X3 Multilabel Plate Reader (PerkinElmer, Waltham, MA, USA) at
485/530 nm. The obtained values were plotted, and the IC50 of artemisinin was calculated
using linear regression analysis.
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In Vivo Functionality of Artemisinin in the Murine Model
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Cryopreserved blood from Plasmodium-infected mice was revived by re-injecting 200 μl of
blood intraperitoneally into Balb/C mice. Giemsa-stained blood smears were made to
determine percentages of parasitemia. After 1 week a mouse was euthanized, and blood was
collected for subsequent experimentation. Four-week-old Balb/C mice were injected with
105 RBCs infected with P. berghei and percentage of parasitemia was determined from
Giemsa-stained blood smears prepared from the tail region. Mice infected with P. berghei
were divided into three groups (four mice in each group). One group of mice was orally
given a single dose (24 mg/kg) of pure artemisinin drug (Sigma-Aldrich, Bengaluru, India),
dissolved in 60 μl of DMSO and reconstituted in water, for nine consecutive days from the
third day post infection; the second group of mice was fed oven-dried leaves from DT4 (500
mg), crushed into fine powder with a homogenizer, mixed with 1 ml of water, and fed by
gavage needle (18 gauge, curved, 2 inches, and 2.25 mm ball diameter); the third group was
fed dried leaves from wild-type plants, prepared as were the DT leaves. All preparations
were freshly prepared before the feeding assay and all treatments were performed in parallel.
Treated parasite cultures were also analyzed microscopically.
Statistical Analysis
The differences of artemisinin and IPP produced in wild-type, T-MEV, and doubly
transgenic lines (DT1–DT4) were tested by one-way ANOVA with Duncan’s multiple range
test, followed by a post hoc analysis (Tallarida and Murray, 1987). Analysis of all samples
was done in triplicate (n = 3).

Supplementary Material
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Schematic Representation of Artemisinin Biosynthesis by Sequential Metabolic
Engineering of Chloroplast and Nuclear Genomes

Author Manuscript

Six genes, AACT, HMGS, HMGRt, MVK, PMK, and PMD (in red font and inside a dotted
rectangle, Supplemental Figure 1A) encoding yeast MEV pathway were integrated into the
chloroplast genome using a biolistic approach to generate an elevated IPP pool. Six genes
(ADS, CYP71AV1, AACPR, DBR2, IDI, and FPP) of the artemisinin biosynthetic pathway
were integrated into the nuclear genome of homoplastomic plants (Supplemental Figure 1B)
using vector pNuc-cox-ART. Subcellular targeting of DBR2, AACPR, and CYP71AV1 were
mediated by a chloroplast transit peptide (Figure 2A). Dihydroartemisinic acid (DHAA)
converts itself to artemisinin via photochemical oxidation, a non-enzymatic reaction. AACT,
acetoacetyl CoA thiolase; HMGS, HMGCoA synthase; HMGRt, C-terminal truncated
HMGCoA reductase; MVK, mevalonate kinase; PMK, phosphomevalonate kinase; PMD,
mevalonate pyrophosphate decarboxylase; DXP, 1-Deoxy-D-xylulose 5-phosphate; MEP, 2C-methyl-D-erythritol 4-phosphate; IPP, isopentenyl diphosphate; IDI, IPP isomerase;
DMAPP, dimethylallyl pyrophosphate; ADS, amorphadiene synthase; FPP, farnesyl
diphosphate; CYP71AV1, amorpha-4,11-diene C-12 oxidase; AACPR, Artemisia annua
cytochrome P450 reductase; DBR2, double bond reductase2.
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Figure 2. Nuclear Genome Transformation of Homoplastomic Plant
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(A) Physical map of the DHAA biosynthetic pathway vector pNuc-cox-Art.
(B) PCR products amplified using primers ADS-F and ADS-R (marked by purple in A) and
DBR2-F and DBR2-R (marked by blue in A) from 12 doubly transgenic (DT1–DT12) plants
yielded a 539-bp and 441-bp amplicon, respectively. No PCR products were observed in
wild-type (WT) plants.
(C) DT plants transferred to a greenhouse grew normally like WT plants and set seeds.
(D) Seeds of matured DT plants germinated and seedlings grew well on double-selection
medium containing hygromycin (50 mg/l) and spectinomycin (500 mg/l). T-MEV and WT
plants lacking essential transgenes conferring resistance to both antibiotics could not
germinate on double-selection medium (see also Supplemental Figure 1).
(E) Four transgenic lines namely DT1–DT4, with elevated artemisinin and DHAA contents
were examined for copy number. Genomic DNA (~15 μg) from DT1–DT4 and WT plants
digested with EcoRV were analyzed by Southern blot using DBR2 as probe (shown as blue
line in vector A).
(F) Total RNA was isolated from DT1–DT4 and resulting cDNAs were amplified using
gene-specific RT–PCR primers of ADS, DBR2, AACPR, and CYP71AV1.
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Figure 3. LC–MS/MS Analysis of Artemisinin Biosynthesized in Double-Transformed Plants
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(A) Chromatographic profile of wild-type plant extract, analyzed in MRM mode for
artemisinin detection.
(B) Extracted ion chromatogram for artemisinin–MRM transition (m/z 283–209) standard
peak shown in red. The artemisinin peak of transgenic (DT4) shown in blue is overlaid with
standard peak (red) at ~5.25 min. No such corresponding peak for artemisinin was observed
in extracts of wild-type (A).
(C) Artemisinin yield quantified in DTs by MultiQuant (ABSciex, Singapore) (see also
Supplemental Table 3). Standard curve was plotted and the R2 coefficient was 0.998.
ANOVA followed by Duncan’s multiple range test demonstrated that the mean artemisinin
levels were significantly different among the lines (P < 0.01). Means followed by the same
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alphabets are not significantly different by Duncan’s multiple range test at P < 0.01, n = 3.
Data are represented as mean ± SD. N.D., not determined; WT, wild-type.
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Figure 4. LC–MS/MS Analysis of Dihydroartemisinic Acid Biosynthesized in DT Plants
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(A–C) Extracted ion chromatogram for dihydroartemisinic acid (DHAA)–MRM transitions
for two fragments m/z 237–163 and m/z 237–107. (A) Standard DHAA peak at retention
time ~11 min. (B) DHAA in DT4. (C) Similar peak was observed in Artemisia annua
extract. An unknown peak was seen at retention time 5.25 min in both DT4 and A. annua
samples. The red and blue lines denote the MRM transitions (163 and 107) for the parent ion
m/z 237 DHAA.
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Figure 5. Comparative LC–MS/MS Analysis of Intermediate Isoprenoid IPP-Metabolite Levels
in Controls (Wild-Type) and Chloroplast Transgenic with Mevalonate Pathway (MEV) and
Double-Transformed Plants (DT1–DT4)
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(A–G) Extracted ion chromatogram of MRM transition (m/z 245–159) for IPP (see also
Supplemental Figure 3) in (A) wild-type, (B) MEV, and (C–F) DT1–DT4. (G) IPP yield
quantified in wild-type (WT), MEV, and DTs by MultiQuant (ABSciex, Singapore). A
standard curve was plotted and the R2 coefficient was 0.998. Analysis of variance (ANOVA)
followed by Duncan’s multiple range test demonstrated that the mean IPP levels were
significantly different among the lines (P < 0.01). Means followed by the same alphabets are
not significantly different by Duncan’s multiple range test at P < 0.01, n = 3. Data are
represented as mean ± SD.
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Figure 6. Accumulation of Amorphadiene in DT4
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(A) Total ion chromatograms from ethyl acetate extract of DT4 plant (upper) and
amorphadiene standard (lower). Peak corresponding to amorphadiene was observed at
retention time ~23 min in the chromatogram of DT4 and amorphadiene standard.
(B) Mass spectra of amorphadiene obtained from the peak in DT4 plant at retention time
~23 min in GC profile.
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Figure 7. In Vitro and In Vivo Efficacy of Artemisinin Biosynthesized in Dual Metabolically
Engineered Plants

(A) In vitro mortality assay of artemisinin from double transformed (DTs) on RBCs infected
with Plasmodium falciparum 3D7. Giemsa staining of RBCs infected with P. falciparum
3D7. No mortality on parasite growth was seen in DMSO, wild-type (WT), and schizonts at
the end of 48 h matured to release the ring-stage parasites. DT1–DT4 extracts controlled
parasite growth in 24–48 h assay.
(B) IC50 values were plotted and calculated using linear regression analysis (see also
Supplemental Figure 4).
(C) Balb/C mice infected with Plasmodium berghei were orally fed for nine consecutive
days (3–11) with dried DT4 leaves (dose equivalent to 24 mg/kg), control wild-type (WT),
and pure drug (Art. drug; equivalent to 24 mg/kg). Arrow in the graph represents the start of
oral feeding on the third day post infection. The error bars represent mean parasitemia ± SD.
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ND
ND
ND
80 ± 6
2.77 ± 0.1

Artemisinin

Dihydroartemisinic acid

Amorphadiene

IPP/DMAPP

Squalene

10 ± 0.5

114 ± 12

ND

ND

ND

T-MEV

27 ± 0.5

175 ± 13

10 ± 5

62 ± 3

331 ± 71

DT1

22 ± 1.1

228 ± 5

53 ± 8

91 ± 6

773 ± 27

DT2

26 ± 0.4

186 ± 13

32 ± 5

82 ± 3

567 ± 76

DT3

21 ± 0.1

253 ± 20

60 ± 5

150 ± 10

877 ± 40

DT4

Values are mean ± SD. ND, not detected. Yield of all metabolites is mentioned in μg/g dry weight except for IPP/DMAPP, which is expressed as ng/g fresh weight, and squalene as μg/g fresh weight. All
values have been rounded to the nearest integer.

WT

Metabolites

Metabolite Profile in Tobacco Lines (DT1–DT4) Engineered with DHAA Biosynthetic Pathway.
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